Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Builds On Tildrakizumab Hopes With Almirall Pact

Executive Summary

Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.

Advertisement

Related Content

Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?
Sun Underlines 'Competitive Profile' Of Psoriasis Asset In Crowded Market
Sun’s Tildrakizumab Shines In Pivotal Psoriasis Trials
Sun Faces Price Pressures In US On Generic Gleevec
Mid-Sized European Companies Eager to Acquire During Growth Spurt
Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment
Hopes Mount On Sun's 'Game Changer' Psoriasis Asset
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
Almirall Aesthetics Takeover

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel